当前位置: 首页 >> 检索结果
4561. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
作者: Eric Wang.;Xiaoli Mi.;Meghan C Thompson.;Skye Montoya.;Ryan Q Notti.;Jumana Afaghani.;Benjamin H Durham.;Alex Penson.;Matthew T Witkowski.;Sydney X Lu.;Jessie Bourcier.;Simon J Hogg.;Caroline Erickson.;Dan Cui.;Hana Cho.;Michael Singer.;Tulasigeri M Totiger.;Sana Chaudhry.;Mark Geyer.;Alvaro Alencar.;Adam J Linley.;M Lia Palomba.;Catherine C Coombs.;Jae H Park.;Andrew Zelenetz.;Lindsey Roeker.;Mary Rosendahl.;Donald E Tsai.;Kevin Ebata.;Barbara Brandhuber.;David M Hyman.;Iannis Aifantis.;Anthony Mato.;Justin Taylor.;Omar Abdel-Wahab.
来源: N Engl J Med. 2022年386卷8期735-743页
Covalent (irreversible) Bruton's tyrosine kinase (BTK) inhibitors have transformed the treatment of multiple B-cell cancers, especially chronic lymphocytic leukemia (CLL). However, resistance can arise through multiple mechanisms, including acquired mutations in BTK at residue C481, the binding site of covalent BTK inhibitors. Noncovalent (reversible) BTK inhibitors overcome this mechanism and other sources of resistance, but the mechanisms of resistance to these therapies are currently not well understood.
4562. Treating Rhythmic and Periodic EEG Patterns in Comatose Survivors of Cardiac Arrest.
作者: Barry J Ruijter.;Hanneke M Keijzer.;Marleen C Tjepkema-Cloostermans.;Michiel J Blans.;Albertus Beishuizen.;Selma C Tromp.;Erik Scholten.;Janneke Horn.;Anne-Fleur van Rootselaar.;Marjolein M Admiraal.;Walter M van den Bergh.;Jan-Willem J Elting.;Norbert A Foudraine.;Francois H M Kornips.;Vivianne H J M van Kranen-Mastenbroek.;Rob P W Rouhl.;Elsbeth C Thomeer.;Walid Moudrous.;Frouke A P Nijhuis.;Suzanne J Booij.;Cornelia W E Hoedemaekers.;Jonne Doorduin.;Fabio S Taccone.;Job van der Palen.;Michel J A M van Putten.;Jeannette Hofmeijer.; .
来源: N Engl J Med. 2022年386卷8期724-734页
Whether the treatment of rhythmic and periodic electroencephalographic (EEG) patterns in comatose survivors of cardiac arrest improves outcomes is uncertain.
4563. Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good.
作者: David J Hunter.;Salim S Abdool Karim.;Lindsey R Baden.;Jeremy J Farrar.;Mary Beth Hamel.;Dan L Longo.;Stephen Morrissey.;Eric J Rubin.
来源: N Engl J Med. 2022年386卷12期1176-1179页 4564. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
作者: Shabir A Madhi.;Gaurav Kwatra.;Jonathan E Myers.;Waasila Jassat.;Nisha Dhar.;Christian K Mukendi.;Amit J Nana.;Lucille Blumberg.;Richard Welch.;Nicoletta Ngorima-Mabhena.;Portia C Mutevedzi.
来源: N Engl J Med. 2022年386卷14期1314-1326页
The B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified on November 25, 2021, in Gauteng province, South Africa. Data regarding the seroprevalence of SARS-CoV-2 IgG in Gauteng before the fourth wave of coronavirus disease 2019 (Covid-19), in which the omicron variant was dominant, are needed.
4567. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
作者: Matthew R Smith.;Maha Hussain.;Fred Saad.;Karim Fizazi.;Cora N Sternberg.;E David Crawford.;Evgeny Kopyltsov.;Chandler H Park.;Boris Alekseev.;Álvaro Montesa-Pino.;Dingwei Ye.;Francis Parnis.;Felipe Cruz.;Teuvo L J Tammela.;Hiroyoshi Suzuki.;Tapio Utriainen.;Cheng Fu.;Motohide Uemura.;María J Méndez-Vidal.;Benjamin L Maughan.;Heikki Joensuu.;Silke Thiele.;Rui Li.;Iris Kuss.;Bertrand Tombal.; .
来源: N Engl J Med. 2022年386卷12期1132-1142页
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.
4568. Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19.
作者: Ariel Hammerman.;Ruslan Sergienko.;Michael Friger.;Tanya Beckenstein.;Alon Peretz.;Doron Netzer.;Shlomit Yaron.;Ronen Arbel.
来源: N Engl J Med. 2022年386卷13期1221-1229页
The risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decreases substantially among patients who have recovered from coronavirus disease 2019 (Covid-19). However, it is unknown how long protective immunity lasts. Current guidelines recommend vaccination of recovered patients even though data regarding vaccine effectiveness in such cases are still limited.
|